Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-09-14
2000-09-12
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514256, A61K 31505
Patent
active
061178799
ABSTRACT:
Moxonidine and its physiologically compatible acid-addition salts are used for the treatment and/or prophylaxis of nociceptive pain, and in particular nociceptive acute and chronic pain.
REFERENCES:
patent: 5447947 (1995-09-01), Campbell
Medline abstract AN 96059841, Urban, R. et al., Aug. 1995.
Armah, B.I., Hofferber, E. and Stenze, W. (1988) "General Pharmacology of the Novel Centrally Acting Antihypertensive Agent Moxonidine". Arzneimittel-Forschung 38: 1426-34.
Codd, E.E., Press, J.B. and Raffa, R.B. (1995) "Alpha 2-Adrenoceptors vs. Imidazoline Receptors: Implications for Alpha 2-Mediated Analgesia and Other Non-Cardiovascular Therapeutic Uses". [Review]. Life Sciences 56:63-74.
Ernsberger, P., Graves, M.E., Graff, L.M., Zakieh, N., Nguyen, P., Collins, A.L., Westbrooks, K.L. and Johnson, G.G. (1995) "I.sub.1 -Imidazoline Receptors: Definition, Characterization, and Transmembrane Signaling". Annals New York Academy of Sciences 763:22-42.
Ferry, D., Armah, B.I., Goll, A. and Glossmann, H. (1988) "Characteristics of the Binding of the Antihypertensive Agent Moxonidine to Alpha 2-Adrenoceptors in Rat Brain Membranes". Arzneimittel-Forschung 38:1442-5.
Hunter, J.C., Fontana, D.J., Hedley, L.R., Jasper, J.R., Lewis, R., Link, R.E., Secchi, R., Sutton, J. and Eglen, R.M. (1997) "Assessment of the Role of .alpha..sub.2 -Adrenoceptor Subtypes in the Antinociceptive, Sedative and Hypothermic Action of Dexmedetomidine in Transgenic Mice". British Journal of Pharmacology 122:1339-44.
Hylden, J.L.K. and Wilcox, G.L. (1981) "Intrathecal Substance P Elicits a Caudally-Directed Biting and Scratching Behavior in Mice". Brain Research 217:212-215.
Hylden, J.L.K. and Wilcox, G.L. (1983) "Pharmacological Characterization of Substance P-Induced Nociception in Mice: Modulation by Opioid and Noradrenergic Agonists at the Spinal Level". The Journal of Pharmacology and Experimental Therapeutics 226:398-404.
Janumpalli, S., Butler, L.S., MacMillan, L.B., Limbird, L.E. and McNamara, J.G. (1998) "A Point Mutation (D79N) of the .alpha.2A Adrenergic Receptor Abolishes the Antiepileptogenic Action of Endogenous Norepinephrine". Journal of Neuroscience 18:2004-2008.
Jones, S.L. and Gebhart, G.F. (1986) "Characterization of Coeruleospinal Inhibition of the Nociceptive Tail-Flick Reflex in the Rat: Mediation by Spinal .alpha..sub.2 -Adrenoceptors". Brian Research 364:315-330.
Lakhlani, P.P., MacMillan, L.B., Guo, T.Z., McCool, B.A., Livinger, D.M., Maze, M. and Limbird, L.E. (1997) "Substitution of a Mutant .alpha..sub.2A -Adrenergic Receptor Via Hit and Run Gene Targeting Reveals the Role of this Subtype in Sedative, Analgesic, and Anesthetic-Sparing Response in vivo". Proceedings of the National Academy of Sciences of the United States of America 94:9950-9955.
Mizobe, T., Maghsoudi, K., Sitwala, K., Tianzhi, G., Ou, J. and Maze, M. (1996) "Antisense Technology Reveals the .alpha..sub.2A Adrenoceptor to be the Subtype Mediating the Hypnotic Response to the Highly Selective Agonist, Dexmedetomidine, in the Locus Coeruleus of the Rat". Journal of Clinical Investigation 98:1076-80.
Monroe, P.J., Smith, D.L. and Smith, D.J. (1995) "Spinal Imidazoline Receptors do not Mediate the Antinociceptive Action of Intrathecal Clonidine in the Rat". Annals New York Academy of Sciences 763:497-500.
Reddy, S.V.R., Maderdrut, J.L. and Yaksh, T.L. (1980) "Spinal Cord Pharmacology of Adrenergic Agonist-Mediated Antinociception". the Journal of Pharmacology and Experimental Therapeutics 213:525-533.
Solomon, R.E., Brody, M.J. and Gebhart, G.F. (1989) "Pharmacological Characterization of Alpha Adrenoceptors Involved in the Antinociceptive And Cardiovascular Effects of Intrathecally Administerd Clonidine". Journal of Pharmacology and Experimental Therapeutics 251:27-38.
Ziegler, D., Haxhiu, M.A., Kaan, E.C., Papp, J.G. and Ernsberger, P. (1996) "Pharmacology of Moxonidine, an I.sub.1 -Imidazoline Receptor Agonist". Journal of Cardiovascular Pharmacology 27:S26-37.
Fairbanks, C.A. and Wilcox, G.L., "Imidazoline Receptor (I.sub.1) Selective Agonists: Antinociceptive Profile Modulation of Morphine Antinociception, and Attenuation of the Development of Morphine Tolerance". Poster Abstract Presented at the 1996 Annual Meeting of the American Pain Society, Nov. 14, 1996.
Fairbanks Carolyn A.
Kitto Kelley F.
Stone Laura S.
Wilcox George L.
Jarvis William R. A.
Solvay Pharmaceuticals GmbH
LandOfFree
Methods of using moxonidine to inhibit nociceptive pain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using moxonidine to inhibit nociceptive pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using moxonidine to inhibit nociceptive pain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-96458